EZH2 and hepatocellular carcinoma: Overexpression of EZH2 is a marker of advanced and metastatic disease in numerous cancers, including bladder cancer [20], gastric cancer [21], lung cancer [22], cervical cancer [23] and hepatocellular carcinoma [24].